Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21199568 | 0.84 | MAPT (0.43) | FFAR1ARMAPTLMNAALDH1A1 | |
| SCHEMBL23229801 | 0.84 | AR (0.39) | FFAR1ARMAPTLMNAALOX5AP | |
| SCHEMBL17187759 | 0.84 | AR (0.39) | FFAR1ARMAPTLMNAALOX5AP | |
| SCHEMBL21199601 | 0.82 | AR (0.43) | FFAR1ARMAPTLMNAALOX5AP | |
| SCHEMBL17187761 | 0.81 | MAPT (0.39) | FFAR1ARMAPTLMNAALOX5AP | |
| SCHEMBL31319587 | 0.81 | MAPT (0.45) | FFAR1ARMAPTLMNAALOX5AP | |
| SCHEMBL31304628 | 0.81 | MAPT (0.49) | FFAR1ARMAPTLMNAALOX5AP | |
| SCHEMBL15200528 | 0.78 | FFAR1 (0.53) | FFAR1ARLMNAALOX5APFEN1 | |
| SCHEMBL17076856 | 0.78 | MEN1 (0.43) | FFAR1ARMAPTLMNAALDH1A1 | |
| SCHEMBL22060829 | 0.77 | FFAR1 (0.51) | FFAR1ALOX5APFEN1PIM1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333414-A1 | HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2025-10-30 | — | — | US | disclosed |
| WO-2025067168-A1 | AZA FUSED RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州爱科百发生物医药技术有限公司 | 2025-04-03 | — | — | WO | disclosed |
| US-12263171-B2 | 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | MERCK SHARP & DOHME LLC (US) | 2025-04-01 | — | — | US | disclosed |
| WO-2025054339-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF KIT | ARCUS BIOSCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025017116-A1 | PHARMACEUTICAL COMPOUNDS HAVING ACTIVITY AS WEE1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2025-01-23 | — | — | WO | disclosed |
| US-12060357-B2 | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | MERCK SHARP & DOHME LLC (US) | 2024-08-13 | — | — | US | disclosed |
| EP-3958867-B1 | SMALL MOLECULE BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | TYRA BIOSCIENCES, INC. | 2024-06-13 | — | — | US | disclosed |
| WO-2024084447-A2 | AZETIDINYL BENZOXAZOLE COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | DONG-A ST CO., LTD. (KR) | 2024-04-25 | — | — | WO | disclosed |
| EP-4297873-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | Tyra Biosciences, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| WO-2014060113-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| US-20130079324-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER INC. | 2013-03-28 | — | — | US | disclosed |
| US-20130079324-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER INC. | 2013-03-28 | — | — | US | disclosed |
| WO-2013042006-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-20130079324-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER INC. | 2013-03-28 | — | — | US | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| EP-2491039-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011048082-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
| WO-2010010184-A1 | [1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010184-A1 | [1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | FFAR1 3820/4885AR 4197/4885MAPT 4393/4885 |
| US-12060357-B2 | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | ADORA2A, ADORA2B, ADORA3 | FFAR1 193/4885AR 519/4885MAPT 4545/4885 |
| US-20250333414-A1 | HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT | STING1, MAVS, TBK1 | FFAR1 1267/4885AR 3652/4885MAPT 4674/4885 |
| US-20130079324-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | TYMP, DPYD, TYMS | FFAR1 3936/4885AR 3970/4885MAPT 4548/4885 |
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | DPYD, TYMP, TYMS | FFAR1 3500/4885AR 350/4885MAPT 3848/4885 |
| US-12263171-B2 | 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | ADORA2A, ADORA2B, ADORA3 | FFAR1 213/4885AR 505/4885MAPT 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.